Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 14/20 | 0.60 |
| ▸ | MMP9 | P14780 | 5/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346338 | 0.86 | BMP1 (0.65) | BMP1MMP9MMP2MMP1MMP13 | |
| SCHEMBL7346333 | 0.86 | BMP1 (0.65) | BMP1MMP9MMP2MMP1MMP13 | |
| Hydrochloric Acid SCHEMBL7382793 | 0.84 | BMP1 (0.56) | BMP1MMP9MMP2MMP1MMP13 | |
| SCHEMBL7417239 | 0.83 | MMP9 (0.57) | BMP1MMP9MMP2MMP1MMP13 | |
| Hydrochloric Acid SCHEMBL7427029 | 0.82 | BMP1 (0.51) | BMP1MMP9MMP2MMP1MMP13 | |
| Hydrochloric Acid SCHEMBL6416821 | 0.81 | BMP1 (0.48) | BMP1MMP9MMP2MMP1MMP13 | |
| SCHEMBL26772448 | 0.81 | MMP9 (0.55) | BMP1MMP9MMP2MMP13 | |
| SCHEMBL6414515 | 0.81 | BMP1 (0.61) | BMP1MMP9MMP2MMP1MMP13 | |
| SCHEMBL2680842 | 0.81 | BMP1 (0.61) | BMP1MMP9MMP2MMP1MMP13 | |
| SCHEMBL26770039 | 0.80 | MMP9 (0.77) | BMP1MMP9MMP2MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | BMP1 3685/4885MMP9 612/4885MMP2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.